Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Clinical Trials on Evaluating the Tolerance, Safety and Efficacy of Autologous TILs in High-risk Recurrent Primary Hepatocellular Carcinoma

NCT04538313 is registered in ClinicalTrials.gov with CAR-T (Shanghai) Cell Biotechnology Co., Ltd. as lead sponsor.

NCT NCT04538313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04538313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Clinical Trials on Evaluating the Tolerance, Safety and Efficacy of Autologous TILs in High-risk Recurrent Primary Hepatocellular Carcinoma
Lead sponsor
CAR-T (Shanghai) Cell Biotechnology Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 26, 2020
Completion date
October 31, 2022
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic carcinoma